On March 3, 2021 Immunophotonics reported that A paper recently published in Cells has described how Immunophotonics’ immune-stimulating drug IP-001 was shown to be effective against metastatic tumors when combined with different forms tumor ablation (Press release, Immunophotonics, MAR 3, 2021, View Source [SID1234576001]). In this review, the authors briefly discuss the current applications of local ablation for cancer treatment and the effects of IP-001 in combination with other ablation therapies, a therapeutic approach that is pioneering the field of Interventional Immuno-Oncology (IIO).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!